Telomerase Cancer Vaccine (GRNVAC1)

We have initiated a Phase II trial of GRNVAC1 in patients with acute myelogenous leukemia (AML) in complete remission. The primary objective of this new Phase II study is to evaluate the safety and feasibility of a prime-boost vaccination regimen that extends the duration of telomerase immunity. Secondary objectives are to evaluate the immune response to GRNVAC1 and to explore the effects of vaccination on minimal residual disease and relapse rates.

Currently, the trial is open for patient enrollment at the following sites:

Washington University
Siteman Cancer Center
St. Louis, MO
Jeremy Gabriel
Telephone: 314-454-5077

University of Texas Southwestern
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
Tracee Rainey, RN
Telephone: 214-648-5102

The Ohio State University Medical Center
Columbus, OH
Patricia Curtis
Telephone: 614-293-8607

Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA
Chizoba Ezekwem
Telephone: 404-778-5319

For a brief synopsis of the GRNVAC1 trial, visit the U.S. National Library of Medicine website at http://www.clinicaltrials.gov